Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.

Michael J. Hall,Talia Golan,Pascal Hammel,Michele Reni,Eric Van Cutsem,Teresa Macarulla,Joon Oh Park,Daniel Hochhauser,Dirk Arnold,Do-Youn Oh,Anke Reinacher-Schick,Giampaolo Tortora,Hana Algül,Eileen M. O’Reilly,David McGuinness,Karen Cui,Seongjung Joo,Hyun Kyoo Yoo,N. Patel,Hedy L. Kindler

Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.

2020

648Background: In POLO (NCT02184195), maintenance O significantly improved progression-free survival vs placebo (P) in pts with a gBRCAm and mPaC without compromising HRQoL (Hammel Ann Oncol 2019)....

Keywords:

Pancreatic cancer
Internal medicine
Quality of life
Germline
Medicine
Oncology
BRCA mutation
Olaparib
Pathology
health related quality of life
in patient
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations